Clinical Trial Update: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update indicating an out-of-specification (OOS) finding for JNJ-68284528 intended for commercial release in participants with multiple m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-68284528

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-27